Literature DB >> 18647801

Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in beta-thalassemic patients.

Amal El Beshlawy1, Galila Mohtar, Esmat Abd El Ghafar, Soha M Abd El Dayem, Manal Hamdy El Sayed, Azza Ahmed Aly, Manal Farok.   

Abstract

OBJECTIVE: To investigate puberty in a group of thalassemic patients with delayed or arrested pubertal development and to compare the effects of hormonal and L-carnitine therapy on puberty in those patients. PATIENTS: Thirty-two -thalassemic patients with arrested or failure of puberty were enrolled for 1 year in this study.
METHOD: Clinical pubertal assessment and laboratory investigations were done for all patients at the beginning, 6 months later clinical pubertal assessment was done. Patients were divided into two groups (16 each): first group received L-carnitine therapy, while the second group received hormonal therapy. Pubertal and laboratory assessment were done 6 months after hormonal and L-carnitine therapy.
RESULTS: Failure of puberty was confirmed in 71.4% of boys and 33.3% of girls, while arrested puberty was observed in 28.6% of boys and 66.7% of girls. All girls had amenorrhea, primary amenorrhea in 88.9% and secondary amenorrhea in 11.1%. Menses occurred in 20% of female patients after L-carnitine therapy and in 37.5% of them after hormonal therapy. Improvement of pubertal staging was observed in 50% of males after L-carnitine therapy compared to 75% of them after hormonal therapy. While improvement of pubertal staging was seen in 90% of females after L-carnitine therapy compared to 100% of females after hormonal treatment. However, these results showed no significant difference between both groups.
CONCLUSION: Delayed puberty in beta-thalassemia major is either due to failure of gonads or failure of the whole hypothalamic pituitary gonadal axis. L-carnitine as well as hormonal replacement therapy had a positive effect on puberty in the thalassemic patients. Further studies are needed to clarify the role of L-carnitine on puberty in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647801     DOI: 10.1093/tropej/fmn043

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  4 in total

Review 1.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

2.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

3.  Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis.

Authors:  Khaled M Salama; Ola M Ibrahim; Ahmed M Kaddah; Samia Boseila; Leila Abu Ismail; May M Abdel Hamid
Journal:  Open Access Maced J Med Sci       Date:  2015-05-28

4.  Health-related quality of life in pediatric and adolescent patients with transfusion-dependent ß-thalassemia in upper Egypt (single center study).

Authors:  Gehan L Abdel Hakeem; Suzan O Mousa; Asmaa N Moustafa; Mohamed H Mahgoob; Ebtesam E Hassan
Journal:  Health Qual Life Outcomes       Date:  2018-04-10       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.